Advanced search
Publication Cover
Expert Review of Molecular Diagnostics Volume 11, 2011 - Issue 5
Submit an article Journal homepage
66
Views
4
CrossRef citations to date
0
Altmetric
Editorial

Ovarian cancer screening and peritoneal carcinomatosis: standards, ‘omics’ and miRNAs for personalized management

John Spiliotis Department of Surgery, METAXA Cancer Memorial Hospital, Botosi 51, TK 18535, Piraeus, Greece
,
Eugenia Halkia Department of Gynaecology, METAXA Cancer Memorial Hospital, Botosi 51, TK 18535, Piraeus, Greece
&
Dimitrios H Roukos Personalized Cancer Genomic Medicine, Biobank, Ioannina University, Ioannina, TK 451 10, Greece and Department of Surgery, Ioannina University School of Medicine, Ioannina, Greece. [email protected]
Pages 465-467 | Published online: 09 Jan 2014

References

  • Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J. Clin.61(2), 69–90 (2011).
  • Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J. Clin.60(5), 277–300 (2010).
  • Clarke-Pearson DL. Clinical practice. Screening for ovarian cancer. N. Engl. J. Med.361(2), 170–177 (2009).
  • Badgwell D, Bast RC Jr. Early detection of ovarian cancer. Dis. Markers23(5–6), 397–410 (2007).
  • Yachida S, Jones S, Bozic I et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature467(7319), 1114–1117 (2010).
  • Brower V. Biomarkers: portents of malignancy. Nature471(7339), S19–S21 (2011).
  • Buchen L. Cancer: missing the mark. Nature471(7339), 428–432 (2011).
  • Visintin I, Feng Z, Longton G et al. Diagnostic markers for early detection of ovarian cancer. Clin. Cancer Res.14, 1065–1072 (2008).
  • Fung ET. A recipe for proteomics diagnostic test development: the OVA1 test, from biomarker discovery to FDA clearance. Clin. Chem.56, 327–329 (2010).
  • Jacobs IJ, Skates SJ, MacDonald N et al. Screening for ovarian cancer: a pilot randomised controlled trial. Lancet353, 1207–1210 (1999).
  • Cramer DW, Bast RC Jr, Berg CD et al. Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens. Cancer Prev. Res.4(3), 365–374 (2011).
  • Zhu CS, Pinsky PF, Cramer DW et al. A framework for evaluating biomarkers for early detection: validation of biomarker panels for ovarian cancer. Cancer Prev. Res.4(3), 375–383 (2011).
  • Rodriguez H, Tezak Z, Mesri M et al. Analytical validation of protein-based multiplex assays: a workshop report by the NCI–FDA interagency oncology task force on molecular diagnostics. Clin. Chem.56(2), 237–243 (2010).
  • du Bois A, Quinn M, Thigpen T et al. 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). Ann. Oncol.16(Suppl. 8), 7–12 (2005)
  • Deraco M, Baratti D, Laterza B et al. Advanced cytoreduction as surgical standard of care and hyperthermic intraperitoneal chemotherapy as promising treatment in epithelial ovarian cancer. Eur. J. Surg. Oncol.37(1), 4–9 (2011).
  • Vergote I, Tropé CG, Amant F et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N. Engl. J. Med.363(10), 943–953 (2010).
  • Armstrong DK, Bundy B, Wenzel L. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N. Engl. J. Med.354(1), 34–43 (2006).
  • Lander ES. Initial impact of the sequencing of the human genome. Nature470(7333), 187–197 (2011).
  • Yang N, Kaur S, Volinia S et al. MicroRNA microarray identifies let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer. Cancer Res.68(24), 10307–10314 (2008).
  • Garzon R, Marcucci G, Croce CM. Targeting microRNAs in cancer: rationale, strategies and challenges. Nat. Rev. Drug Discov.9(10), 775–789 (2010).
  • Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell144(5), 646–674 (2011).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.